Harmonising Bioequivalence: Advancing Global Access to Generic Medicines

STADA’s Stephan Eder sets Access, Manufacturing and Sustainability at heart of Medicines for Europe Presidency

Industry Proposes Phased Rollout of ePI for Patient Safety and Environmental Sustainability

Maximising the impact of Biosimilar Medicines requires strategic action in Europe

Medicines for Europe Statement on Unitary SPC Legislative Process

Joint Industry Statement on EU-Mercosur Negotiations

Council adoption of Urban Waste Water Treatment Directive will generate a tsunami of essential and critical medicine shortages across Europe

New report highlights market access barriers for EU-based generic and biosimilar companies in third countries

Urban Wastewater Treatment Directive risks undoing Europe’s efforts to improve the availability, affordability and accessibility of medicines

Medicines for Europe delegation leads on manufacturing, sustainability and access at CPHI congress